In this episode, I zoom way out from “just bones” and show you why orthopedics is inseparable from the rest of medicine—using a brutal, very real leukemia story as the thread. I break down Tatiana Schlossberg’s battle with acute myeloid leukemia (AML) shortly after childbirth, why certain high-risk genetics (like inversion 3) can change prognosis, and what that means when you’re trying to choose between standard chemo, clinical trials, or experimental options. This is the part people don’t like to talk about: biology doesn’t care who you are, and outcomes can hinge on whether research exists—and whether it’s funded. Then I connect the dots to policy. When governments cut research budgets, it’s not some abstract “future problem.” It directly slows down the therapies we’re all waiting for—CAR T-style approaches, next-gen targeted drugs, and the mRNA vaccine platform being adapted for cancer. And yes, as an ortho surgeon, I care because cancer care affects bones all the time: marrow disease, fragility, steroid side effects, chemo-related bone loss, and the orthopedic complications that follow. My takeaway is simple: evidence-based medicine needs evidence, and evidence needs funding—because the breakthroughs that save lives (and preserve function) don’t appear by magic.